452 related articles for article (PubMed ID: 27507629)
1. Benefit from cytoreductive nephrectomy and the prognostic role of neutrophil-to-lymphocyte ratio in patients with metastatic renal cell carcinoma.
Day D; Kanjanapan Y; Kwan E; Yip D; Lawrentschuk N; Davis ID; Azad AA; Wong S; Rosenthal M; Gibbs P; Tran B
Intern Med J; 2016 Nov; 46(11):1291-1297. PubMed ID: 27507629
[TBL] [Abstract][Full Text] [Related]
2. Cytoreductive nephrectomy in patients with synchronous metastases from renal cell carcinoma: results from the International Metastatic Renal Cell Carcinoma Database Consortium.
Heng DY; Wells JC; Rini BI; Beuselinck B; Lee JL; Knox JJ; Bjarnason GA; Pal SK; Kollmannsberger CK; Yuasa T; Srinivas S; Donskov F; Bamias A; Wood LA; Ernst DS; Agarwal N; Vaishampayan UN; Rha SY; Kim JJ; Choueiri TK
Eur Urol; 2014 Oct; 66(4):704-10. PubMed ID: 24931622
[TBL] [Abstract][Full Text] [Related]
3. Survival of patients undergoing cytoreductive surgery for metastatic renal cell carcinoma in the targeted-therapy era.
Abern MR; Scosyrev E; Tsivian M; Messing EM; Polascik TJ; Dudek AZ
Anticancer Res; 2014 May; 34(5):2405-11. PubMed ID: 24778051
[TBL] [Abstract][Full Text] [Related]
4. Comparative Effectiveness of Initial Surgery vs Initial Systemic Therapy for Metastatic Kidney Cancer in the Targeted Therapy Era: Analysis of a Population-based Cohort.
Macleod LC; Odisho AY; Tykodi SS; Holt SK; Harper JD; Gore JL
Urology; 2018 Mar; 113():146-152. PubMed ID: 29174942
[TBL] [Abstract][Full Text] [Related]
5. Prognostic significance of cytoreductive nephrectomy in patients with synchronous metastases from renal cell carcinoma treated with first-line sunitinib: a European multiinstitutional study.
Bamias A; Tzannis K; Papatsoris A; Oudard S; Beuselinck B; Escudier B; Liontos M; Elaidi TR; Chrisofos M; Stravodimos K; Anastasiou I; Mitropoulos D; Deliveliotis C; Constantinides C; Dimopoulos MA; Bamia C
Clin Genitourin Cancer; 2014 Oct; 12(5):373-83. PubMed ID: 24819319
[TBL] [Abstract][Full Text] [Related]
6. Analysis of pre-operative variables for identifying patients who might benefit from upfront cytoreductive nephrectomy for metastatic renal cell carcinoma in the targeted therapy era.
You D; Jeong IG; Song C; Lee JL; Hong B; Hong JH; Ahn H; Kim CS
Jpn J Clin Oncol; 2015 Jan; 45(1):96-102. PubMed ID: 25341544
[TBL] [Abstract][Full Text] [Related]
7. Association of preoperative serum De Ritis ratio with oncological outcomes in patients treated with cytoreductive nephrectomy for metastatic renal cell carcinoma.
Laukhtina E; Pradere B; D Andrea D; Rosiello G; Luzzago S; Pecoraro A; Palumbo C; Knipper S; Karakiewicz PI; Margulis V; Quhal F; Sari Motlagh R; Mostafaei H; Mori K; Kimura S; Enikeev D; Shariat SF
Urol Oncol; 2020 Dec; 38(12):936.e7-936.e14. PubMed ID: 32962909
[TBL] [Abstract][Full Text] [Related]
8. The independent oncological role for cytoreductive nephrectomy in metastatic renal cell carcinoma: Prognostic features in the era of targeted therapies.
Claeys T; Lumen N; Kumps C; Praet M; De Meerleer G; Rottey S; Ost P; Devisschere P; Villeirs G; Fonteyne V; Decaestecker K
Urol Oncol; 2017 Apr; 35(4):152.e13-152.e22. PubMed ID: 28153420
[TBL] [Abstract][Full Text] [Related]
9. Oncologic Outcomes of Cytoreductive Nephrectomy in Synchronous Metastatic Renal-Cell Carcinoma: A Single-Center Experience.
Choi CI; Kang M; Sung HH; Jeon HG; Jeong BC; Jeon SS; Lee HM; Seo SIL
Clin Genitourin Cancer; 2018 Dec; 16(6):e1189-e1199. PubMed ID: 30262447
[TBL] [Abstract][Full Text] [Related]
10. Impact of Cytoreductive Nephrectomy on Survival in Patients with Metastatic Renal Cell Carcinoma Treated by Targeted Therapy.
Song Y; Du CX; Zhang W; Sun YK; Yang L; Cui CX; Chi YB; Shou JZ; Zhou AP; Li CL; Ma JH; Wang JW; Sun Y
Chin Med J (Engl); 2016 Mar; 129(5):530-5. PubMed ID: 26904986
[TBL] [Abstract][Full Text] [Related]
11. Nephrectomy improves overall survival in patients with metastatic renal cell carcinoma in cases of favorable MSKCC or ECOG prognostic features.
Mathieu R; Pignot G; Ingles A; Crepel M; Bigot P; Bernhard JC; Joly F; Guy L; Ravaud A; Azzouzi AR; Gravis G; Chevreau C; Zini L; Lang H; Pfister C; Lechevallier E; Fais PO; Berger J; Vayleux B; Roupret M; Audenet F; Descazeaud A; Rigaud J; Machiels JP; Staehler M; Salomon L; Ferriere JM; Kleinclauss F; Bensalah K; Patard JJ
Urol Oncol; 2015 Aug; 33(8):339.e9-15. PubMed ID: 26087971
[TBL] [Abstract][Full Text] [Related]
12. Cytoreductive Nephrectomy in Elderly Patients with Metastatic Renal Cell Carcinoma in the Targeted Therapy Era.
Uprety D; Bista A; Smith AL; Vallatharasu Y; Marinier DE
Anticancer Res; 2018 May; 38(5):3013-3018. PubMed ID: 29715133
[TBL] [Abstract][Full Text] [Related]
13. Systematic Review of the Role of Cytoreductive Nephrectomy in the Targeted Therapy Era and Beyond: An Individualized Approach to Metastatic Renal Cell Carcinoma.
Bhindi B; Abel EJ; Albiges L; Bensalah K; Boorjian SA; Daneshmand S; Karam JA; Mason RJ; Powles T; Bex A
Eur Urol; 2019 Jan; 75(1):111-128. PubMed ID: 30467042
[TBL] [Abstract][Full Text] [Related]
14. Deferred Cytoreductive Nephrectomy in Patients with Newly Diagnosed Metastatic Renal Cell Carcinoma.
Bhindi B; Graham J; Wells JC; Bakouny Z; Donskov F; Fraccon A; Pasini F; Lee JL; Basappa NS; Hansen A; Kollmannsberger CK; Kanesvaran R; Yuasa T; Ernst DS; Srinivas S; Rini BI; Bowman I; Pal SK; Choueiri TK; Heng DYC
Eur Urol; 2020 Oct; 78(4):615-623. PubMed ID: 32362493
[TBL] [Abstract][Full Text] [Related]
15. The Role of Cytoreductive Nephrectomy in Metastatic Renal Cell Carcinoma: A Real-World Multi-Institutional Analysis.
Ghatalia P; Handorf EA; Geynisman DM; Deng M; Zibelman MR; Abbosh P; Anari F; Greenberg RE; Viterbo R; Chen D; Smaldone MC; Kutikov A; Uzzo RG
J Urol; 2022 Jul; 208(1):71-79. PubMed ID: 35212574
[TBL] [Abstract][Full Text] [Related]
16. The Value of Neutrophil to Lymphocyte Ratio in Patients Undergoing Cytoreductive Nephrectomy with Thrombectomy.
Peyton CC; Abel EJ; Chipollini J; Boulware DC; Azizi M; Karam JA; Margulis V; Master VA; Matin SF; Raman JD; Sexton WJ; Wood CG; Spiess PE
Eur Urol Focus; 2020 Jan; 6(1):104-111. PubMed ID: 30206003
[TBL] [Abstract][Full Text] [Related]
17. Impact of Primary Tumor Size on Prognosis in Patients With Metastatic Renal Cell Carcinoma Receiving Cytoreductive Nephrectomy: A Population Study of a Chinese Center and the US SEER Database.
Jiang W; Shou J; Shi H; Wen L; Zhang H; Zheng S; Li C; Ma J
Technol Cancer Res Treat; 2021; 20():15330338211019507. PubMed ID: 34032149
[TBL] [Abstract][Full Text] [Related]
18. Upfront Cytoreductive Nephrectomy for Metastatic Renal Cell Carcinoma Treated with Immune Checkpoint Inhibitors or Targeted Therapy: An Observational Study from the International Metastatic Renal Cell Carcinoma Database Consortium.
Bakouny Z; El Zarif T; Dudani S; Connor Wells J; Gan CL; Donskov F; Shapiro J; Davis ID; Parnis F; Ravi P; Steinharter JA; Agarwal N; Alva A; Wood L; Kapoor A; Ruiz Morales JM; Kollmannsberger C; Beuselinck B; Xie W; Heng DYC; Choueiri TK
Eur Urol; 2023 Feb; 83(2):145-151. PubMed ID: 36272943
[TBL] [Abstract][Full Text] [Related]
19. Overall survival in patients with metastatic renal cell carcinoma and clinical N1 disease undergoing cytoreductive nephrectomy and lymph node dissection.
Faiena I; Salmasi A; Lenis AT; Donin NM; Johnson DC; Bachour K; Drakaki A; Belldegrun AS; Pantuck AJ; Chamie K
Urol Oncol; 2018 Feb; 36(2):79.e19-79.e26. PubMed ID: 29103965
[TBL] [Abstract][Full Text] [Related]
20. Cytoreductive nephrectomy with thrombectomy before targeted therapy improves survival for metastatic renal cell carcinoma with venous tumor thrombus: a single-center experience.
Qi N; Wu P; Chen J; Li T; Ning X; Wang J; Gong K
World J Surg Oncol; 2017 Jan; 15(1):4. PubMed ID: 28056988
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]